2003
DOI: 10.3233/hab-2002-11403
|View full text |Cite
|
Sign up to set email alerts
|

Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies

Abstract: The unique features of monoclonal antibodies (specificity, effectiveness, purity and unlimited reproducibility) make them ideal tools for the specific treatment of all kind of diseases. The third generation of monoclonal antibodies for the treatment of human diseases will be, after murine and "humanised' murine immunoglobulins, fully human antibodies. The best source of human monoclonal antibodies are the antibody pools of cancer patients themselves with the best technique for generating them being conventiona… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
13
0

Year Published

2004
2004
2020
2020

Publication Types

Select...
5
4

Relationship

2
7

Authors

Journals

citations
Cited by 28 publications
(13 citation statements)
references
References 105 publications
0
13
0
Order By: Relevance
“…After 15 years of experience with the human antibody technology and human IgMs, the majority of the technical problems concerning low affinity and cross-reactivity of human IgM antibodies are nearly solved (41). Several interesting human natural IgM antibodies have already been established that are useful for diagnostic purposes and have been successfully used in clinical trials (13,21,22).…”
Section: Discussionmentioning
confidence: 99%
“…After 15 years of experience with the human antibody technology and human IgMs, the majority of the technical problems concerning low affinity and cross-reactivity of human IgM antibodies are nearly solved (41). Several interesting human natural IgM antibodies have already been established that are useful for diagnostic purposes and have been successfully used in clinical trials (13,21,22).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover such MAbs have a low risk for immunogenicity in man, as they are human, and often have few or no somatic mutations (Bra¨ndlein et al 2003b). An intriguing complication is that most, if not all, tumor reactive antibodies isolated from cancer patients are IgMs (Vollmers & Bra¨ndlein 2002), necessitating either isotype switching or molecular reconfiguration to an IgG (Pancook et al 2001) to facilitate preclinical and clinical development. Several tumor-selective IgMs from cancer patients have been used to identify their cognate antigens including SC-1 (Hensel et al 1999) and PAM-1 (Bra¨ndlein et al 2003a).…”
Section: Human Hybridomasmentioning
confidence: 99%
“…The immunogenicity of murine MAbs has often been reduced to inconsequential levels by chimerization or preferably humanization, as extensively reviewed elsewhere (Carter 2001, Brekke & Sandlie 2003, Glennie & van de Winkel 2003. Murine MAb humanization can be obviated by using human MAb from phage display libraries (Hoogenboom 2002), transgenic mice that express human antibodies (Davis et al 2004), patients (Vollmers & Bra¨ndlein 2002), or selected lymphocyte antibody methods (Babcook et al 1996) (Table 2). Whilst human antibodies have the potential to streamline preclinical development, each method for human MAb generation poses unique challenges for research applications (see below).…”
Section: Antibody Technologiesmentioning
confidence: 99%
“…They are germ-line coded and possess low affinity, and their targets are post-translationally modified cell surface antigens. The epitopes are, in most cases, carbohydrate structures (4,5).…”
Section: Introductionmentioning
confidence: 99%